Recursion Pharmaceuticals, Inc. $RXRX Shares Purchased by EverSource Wealth Advisors LLC

Key Points

• EverSource Wealth Advisors LLC significantly increased its stake in Recursion Pharmaceuticals by 94,360% during the first quarter, acquiring a total of 108,629 shares valued at $575,000.
• Several other institutional investors, including Man Group plc and Rockefeller Capital Management, also raised their stakes, indicating strong institutional interest, with approximately 89.06% of shares held by institutional investors.
• Recursion Pharmaceuticals reported a negative EPS of ($0.41) for the last quarter, missing analysts' estimates, despite achieving a 33.3% increase in revenue compared to the same quarter last year.

EverSource Wealth Advisors LLC lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 94,360.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,629 shares of the company's stock after purchasing an additional 108,514 shares during the period. EverSource Wealth Advisors LLC's holdings in Recursion Pharmaceuticals were worth $575,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after purchasing an additional 2,026 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $54,000. San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $54,000. Finally, ADG Wealth Management Group LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $55,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Insider Activity

In other news, insider Najat Khan sold 36,599 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 8.43% of the company's stock.

Recursion Pharmaceuticals Stock Up 0.2%

Shares of Recursion Pharmaceuticals stock traded up $0.01 during trading hours on Thursday, hitting $4.78. The company had a trading volume of 14,513,675 shares, compared to its average volume of 24,828,965. The company's 50-day moving average is $5.47 and its two-hundred day moving average is $5.80. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The company has a market cap of $2.08 billion, a P/E ratio of -2.69 and a beta of 0.93.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. During the same quarter in the previous year, the company posted ($0.40) EPS. The company's quarterly revenue was up 33.3% on a year-over-year basis. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RXRX has been the subject of several analyst reports. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reiterated a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.